Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eli Lilly and CoXSWX:LLY 93 Days Sales Outstanding is 75.93 as of Jun. 2026, which is 4% below its 10-year median of 79.45. GuruFocus rates XSWX:LLY with a GF Score™ of 93/100 and a GF Value™ of CHF1,208.54 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 949 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 56.16% on this metric.
The historical rank and industry rank for Eli Lilly and Co's Days Sales Outstanding or its related term are showing as below:
XSWX:LLY'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.86 Med: 79.45 Max: 86.76
Current: 79.31
During the past 13 years, Eli Lilly and Co's highest Days Sales Outstanding was 86.76. The lowest was 64.86. And the median was 79.45.
XSWX:LLY's Days Sales Outstanding is ranked worse than 56.16% of 949
companies
in the Drug Manufacturers industry
Industry Median: 72.18
vs XSWX:LLY: 79.31
Eli Lilly and Co's Days Sales Outstanding
declined
from Jun. 2025 (79.91) to Jun. 2026 (75.93).
Eli Lilly and Co (XSWX:LLY) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Eli Lilly and Co Days Sales Outstanding Related Terms
Eli Lilly and Co Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:LLY vs JNJ, ABBV, MRK: Days Sales Outstanding Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Days Sales Outstanding falls into.
Eli Lilly and Co Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (XSWX:LLY) has a Days Sales Outstanding of 75.93 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Eli Lilly and Co and its competitors. This is near median its historical median of 79.45. Over the past decade, Eli Lilly and Co's Days Sales Outstanding has ranged from 64.86 to 86.76. According to the industry distribution chart, Eli Lilly and Co ranks #533 out of 949 companies in the Drug Manufacturers industry, placing it in the top 56.2%.
Is Eli Lilly and Co's Days Sales Outstanding too high?
Eli Lilly and Co's current Days Sales Outstanding of 75.93 is near median its 10-year median of 79.45. Over the past 10 years, this metric has ranged from a low of 64.86 to a high of 86.76. The Drug Manufacturers industry median Days Sales Outstanding is 72.18. Eli Lilly and Co's value of 75.93 is 5.2% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #533 out of 949 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eli Lilly and Co has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Days Sales Outstanding compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #533 out of 949 companies for Days Sales Outstanding. This places Eli Lilly and Co in the lower half of its industry. The industry median Days Sales Outstanding is 72.18. Eli Lilly and Co's value of 75.93 is 5.2% above this benchmark. Historically, Eli Lilly and Co's own Days Sales Outstanding has ranged from 64.86 to 86.76 over the past decade. While the company's 10-year median is 79.45 vs. the industry median of 72.18, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 72.18, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current Days Sales Outstanding of 75.93 is 5.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 72.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current Days Sales Outstanding is 75.93, which is near median its own 10-year median of 79.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,208.54, compared to a current price of CHF955.00 — trading 21% below its estimated fair value. The current Days Sales Outstanding is 75.93, which is near median its 10-year median of 79.45 and 5.2% above the Drug Manufacturers industry median of 72.18. Eli Lilly and Co's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Days Sales Outstanding is 75.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF955.00 is trading 21% below its estimated GF Value™ of CHF1,208.54.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
Days Sales Outstanding: 75.93 (near median its 10-year median of 79.45)
GF Value™: CHF1,208.54 vs. price of CHF955.00 (21% below fair value)
Industry Position: 5.2% above the Drug Manufacturers median (#533 of 949)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
93GF Score
Get the complete analysis for XSWX:LLY
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
